1/
Long COVID and post-acute COVID-19 vaccination syndrome (PACVS) share the same core picture: fatigue, brain fog, post-exertional malaise, dysautonomia.
No routine clinical test separates them. What does the biomarker research show? 🧵
Fig: Purpura et al., Clin Infect Dis 2026 (CC BY-NC-ND 4.0)
I've been reading published studies of neurotransmitter differences in long COVID versus comparison groups. The most consistent finding is reduced GABA-B inhibition on TMS. Two 2026 papers now point to catecholamines, while peripheral serotonin is still contested.
#LongCOVID
I found no neurotransmitter study in PACVS — a gap, not evidence of no difference. Next: independent replication of the 2026 PET and CSF findings, and serotonin assays that handle platelets and SSRI use carefully. Observational only.
#LongCOVID#PACVS#LakshmiPriya
I've been reading published studies of neurotransmitter differences in long COVID versus comparison groups. The most consistent finding is reduced GABA-B inhibition on TMS. Two 2026 papers now point to catecholamines, while peripheral serotonin is still contested.
#LongCOVID
Kynurenines came up in the last thread. Cysique 2023 saw early rises vs reference ranges. Matits 2026 (127 vs 91) found associations, not a clear difference. Almulla 2024: lower tryptophan (SMD −0.52) and higher KYN/TRP (SMD 0.76).
https://t.co/BbEffIWSzP
https://t.co/YSwAVDZqeO
DocuSign wants $8,100/yr from a 15-person team just to sign PDFs. So I built SignuDoc: open source, one-click deploy to your own @vercel account, $0 per seat.
White-label branding, full audit trails, tamper-evident seals and your documents never leave your cloud.
In this video I walk through published metabolomic studies of blood metabolites in long COVID versus healthy controls. Similar exercise intolerance has been described in PACVS, but dedicated metabolomic datasets are still few.
https://t.co/C7pscE205e
#LongCOVID#PACVS
PACVS shows overlapping exercise findings, but we still have very few dedicated metabolomic datasets. Open questions for me are how common these signatures are outside selected cohorts, and whether the metabolites move as symptoms change. Head-to-head studies would help.